Xerava (eravacycline) is a small molecule pharmaceutical. Eravacycline was first approved as Xerava on 2018-08-27. It is used to treat intraabdominal infections in the USA. It has been approved in Europe to treat bacterial infections and infections. Xerava's patents are valid until 2030-12-28 (FDA).
|Indication||bacterial infections, infections, intraabdominal infections|
|Drug Class||Antibiotics (tetracycline derivatives)|